Literature DB >> 28868734

A Supplement to TRANSFUSION Abstract Presentations from the AABB Annual Meeting San Diego, CA, October 7-10, 2017.

.   

Abstract

Year:  2017        PMID： 28868734      PMCID： PMC7169716          DOI： 10.1111/trf.14286

Source DB:  PubMed          Journal:  Transfusion        ISSN： 0041-1132            Impact factor:   3.157


× No keyword cloud information.
  10 in total

1.  Causes of hemolysis in neonates with extreme hyperbilirubinemia.

Authors:  R D Christensen; R H Nussenzveig; H M Yaish; E Henry; L D Eggert; A M Agarwal
Journal:  J Perinatol       Date:  2014-04-24       Impact factor: 2.521

Review 2.  Immune hemolytic anemia associated with negative routine serology.

Authors:  George Garratty
Journal:  Semin Hematol       Date:  2005-07       Impact factor: 3.851

Review 3.  The autoimmune haemolytic anaemias.

Authors:  S M Worlledge; M A Blajchman
Journal:  Br J Haematol       Date:  1972-09       Impact factor: 6.998

4.  Clinical usefulness of specific antiglobulin reagents in autoimmune hemolytic anemias.

Authors:  H Chaplin
Journal:  Prog Hematol       Date:  1973

5.  Unusually severe ABO hemolytic disease of newborn.

Authors:  J Goraya; S Basu; P Sodhi; S Mehta
Journal:  Indian J Pediatr       Date:  2001-03       Impact factor: 1.967

6.  Hydrops fetalis due to ABO incompatibility.

Authors:  M McDonnell; S Hannam; S P Devane
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-05       Impact factor: 5.747

7.  Maternal IgG anti-A and anti-B titres predict outcome in ABO-incompatibility in the neonate.

Authors:  Egil Bakkeheim; Unni Bergerud; Anne-Christine Schmidt-Melbye; Ciğdem Akalin Akkök; Knut Liestøl; Drude Fugelseth; Rolf Lindemann
Journal:  Acta Paediatr       Date:  2009-08-24       Impact factor: 2.299

8.  Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases.

Authors:  Gwen M Wilkie; Clare Taylor; Marie M Jones; David M Burns; Marc Turner; David Kilpatrick; Peter L Amlot; Dorothy H Crawford; Tanzina Haque
Journal:  J Immunother       Date:  2004 Jul-Aug       Impact factor: 4.456

9.  Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

Authors:  Tanzina Haque; Gwen M Wilkie; Marie M Jones; Craig D Higgins; Gillian Urquhart; Phoebe Wingate; David Burns; Karen McAulay; Marc Turner; Christopher Bellamy; Peter L Amlot; Deirdre Kelly; Alastair MacGilchrist; Maher K Gandhi; Anthony J Swerdlow; Dorothy H Crawford
Journal:  Blood       Date:  2007-04-27       Impact factor: 22.113

10.  Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.

Authors:  Ulrike Gerdemann; Jacqueline M Keirnan; Usha L Katari; Ryu Yanagisawa; Anne S Christin; Leslie E Huye; Serena K Perna; Sravya Ennamuri; Stephen Gottschalk; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Ann M Leen
Journal:  Mol Ther       Date:  2012-07-17       Impact factor: 11.454
  10 in total
  2 in total

1.  Supplemental findings of the 2017 National Blood Collection and Utilization Survey.

Authors:  Mathew R P Sapiano; Jefferson M Jones; Alexandra A Savinkina; Kathryn A Haass; James J Berger; Sridhar V Basavaraju
Journal:  Transfusion       Date:  2020-03       Impact factor: 3.337

2.  Supply and demand for plasma-derived medicinal products - A critical reassessment amid the COVID-19 pandemic.

Authors:  Jan Hartmann; Harvey G Klein
Journal:  Transfusion       Date:  2020-09-09       Impact factor: 3.337
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.